CXCR2 and chronic myelogenous leukemia, BCR-ABL1 positive: Combining CXCR2 antagonist with TKIs effectively inhibits LSC proliferation in CML, significantly enhancing the inhibitory effect on leukemia cells and LSCs while promoting CML cell apoptosis.